{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:37:43Z","timestamp":1784972263328,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"NIH","award":["P01-CA52477-17"],"award-info":[{"award-number":["P01-CA52477-17"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ygyno.2011.07.019","type":"journal-article","created":{"date-parts":[[2011,8,21]],"date-time":"2011-08-21T07:22:21Z","timestamp":1313911341000},"page":"196-199","source":"Crossref","is-referenced-by-count":10,"title":["Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers"],"prefix":"10.1016","volume":"123","author":[{"given":"David M.","family":"Hyman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela G.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel N.","family":"Grisham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Iasonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noah D.","family":"Kauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Spriggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2011.07.019_bb0005","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0010","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/cncr.21536","article-title":"BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases","volume":"104","author":"Pal","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0015","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1086\/318787","article-title":"Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer","volume":"68","author":"Risch","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0020","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/jnci\/94.18.1365","article-title":"Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program","volume":"94","author":"Brose","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1086\/301749","article-title":"Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium","volume":"62","author":"Ford","year":"1998","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0030","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa020119","article-title":"Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation","volume":"346","author":"Kauff","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0035","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1056\/NEJMoa012158","article-title":"Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations","volume":"346","author":"Rebbeck","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0040","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.2007.11.6905","article-title":"Effect of BRCA1\/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer","volume":"26","author":"Chetrit","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0045","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1200\/JCO.20.2.463","article-title":"Effect of BRCA mutations on the length of survival in epithelial ovarian tumors","volume":"20","author":"Ben David","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0050","first-page":"1120","article-title":"BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II)","volume":"58","author":"Husain","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0060","doi-asserted-by":"crossref","first-page":"5530","DOI":"10.1200\/JCO.2008.16.1703","article-title":"\u201cBRCAness\u201d syndrome in ovarian cancer: a case\u2013control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations","volume":"26","author":"Tan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/annonc\/mdq577","article-title":"Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity","volume":"22","author":"Gallagher","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0070","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0075","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ygyno.2010.11.008","article-title":"A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study (GOG 146Q)","volume":"120","author":"Herzog","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0080","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2009.27.8911","article-title":"Topotecan weekly versus conventional 5-day schedule in patients with platinum-resistant ovarian cancer: a randomized multicenter phase II trial of the north-eastern German society of gynecological oncology ovarian cancer study group","volume":"29","author":"Sehouli","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0085","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0090","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","article-title":"DNA topoisomerases and their poisoning by anticancer and antibacterial drugs","volume":"17","author":"Pommier","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0095","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","article-title":"Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)","volume":"96","author":"Rustin","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0100","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/nature06633","article-title":"Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers","volume":"451","author":"Sakai","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0105","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nature06548","article-title":"Resistance to therapy caused by intragenic deletion in BRCA2","volume":"451","author":"Edwards","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2011.07.019_bb0110","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-09-3367","article-title":"Sensitivity and acquired resistance of BRCA1; p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan","volume":"70","author":"Zander","year":"2010","journal-title":"Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811005695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825811005695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T06:32:48Z","timestamp":1560493968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825811005695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0090825811005695"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2011.07.019","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}